Protocols

AbbVie partners on an Opdivo combo study with Bristol-Myers; Intercept tumbles on FDA warning

⇨ AbbVie wants to explore how a combination of its anti-c-Met antibody drug ABBV-399 will work in combination with Bristol-Myers’ Opdivo in treating non-small cell lung cancer. This is the latest in hundreds of combo studies with checkpoint drugs, and AbbVie is taking the lead on executing the Phase Ib study.

⇨ Shares of Intercept Pharmaceuticals $ICPT tumbled badly after the FDA issued a warning about the risk of death and injury patients face taking their drug Ocaliva. Some analysts speculate that the FDA may be about to slap a black box warning on the drug — sold for primary biliary cholangitis — that could crimp sales.

⇨ Interested in the industry’s pipeline of new Alzheimer’s drugs? If so, you should check out PhRMA’s new list covering dozens of experimental meds in the clinic.



The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biomanufacturing